PREDICTORS OF DEEP MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE: AN ANALYSIS BY THE GIMEMA CML WP

被引：0

作者：

Castagnetti, F. ^{[1
]}

Gugliotta, G. ^{[1
]}

Breccia, M. ^{[2
]}

Specchia, G. ^{[3
]}

Binotto, G. ^{[4
]}

Abruzzese, E. ^{[5
]}

Iurlo, A. ^{[6
]}

Vigneri, P. ^{[7
]}

Cavazzini, F. ^{[8
]}

Intermesoli, T. ^{[9
]}

Ferrero, D. ^{[10
]}

Martino, B. ^{[11
]}

Leoni, P. ^{[12
]}

Bocchia, M. ^{[13
]}

Rege-Cambrin, G. ^{[14
]}

Gherlinzoni, F. ^{[15
]}

Bochicchio, M. T. ^{[1
]}

Soverini, S. ^{[1
]}

Alimena, G. ^{[2
]}

Pane, F. ^{[16
]}

Saglio, G. ^{[14
]}

Cavo, M. ^{[1
]}

Martinelli, G. ^{[1
]}

Baccarani, M. ^{[17
]}

Rosti, G. ^{[1
]}

机构：

[1] Univ Bologna, Inst Hematol L&A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[2] Univ Roma La Sapienza, Chair Hematol, I-00185 Rome, Italy

[3] Univ Bari, Chair Hematol, Bari, Italy

[4] Univ Padua, Chair Hematol, Padua, Italy

[5] S Eugenio Hosp, Hematol Unit, Rome, Italy

[6] Fdn IRCCS Ca Granda Osped Maggiore, Hematol Unit, Milan, Italy

[7] Univ Catania, Chair Hematol, Catania, Italy

[8] Univ Ferrara, Chair Hematol, I-44100 Ferrara, Italy

[9] Osped Riuniti Bergamo, Hematol Unit, I-24100 Bergamo, Italy

[10] Univ Turin, Chair Hematol, Turin, Italy

[11] Osped Riuniti Reggio Calabria, Hematol Unit, Reggio Di Calabria, Italy

[12] Torrette Univ Hosp, Chair Hematol, Ancona, Italy

[13] Univ Siena, Chair Hematol, I-53100 Siena, Italy

[14] S Luigi Gonzaga Univ Hosp, Chair Hematol, Orbassano, TO, Italy

[15] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

[16] Univ Naples Federico II, Chair Hematol, Naples, Italy

[17] Univ Bologna, Dept Hematol & Oncol L&A Seragnoli, Bologna, Italy

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S810

引用

页码：324 / 324

页数：1

共 50 条

[21] Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
Gugliotta, Gabriele
Castagnetti, Fausto
Palandri, Francesca
Breccia, Massimo
Intermesoli, Tamara
Capucci, Adele
Martino, Bruno
Pregno, Patrizia
Rupoli, Serena
Ferrero, Dario
Gherlinzoni, Filippo
Montefusco, Enrico
Bocchia, Monica
Tiribelli, Mario
Pierri, Ivana
Grifoni, Federica
Marzocchi, Giulia
Amabile, Marilina
Testoni, Nicoletta
Martinelli, Giovanni
Alimena, Giuliana
Pane, Fabrizio
Saglio, Giuseppe
Baccarani, Michele
Rosti, Gianantonio
BLOOD, 2011, 117 (21) : 5591 - 5599
[22] Imatinib mesylate determines a high frequency of major molecular responses in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CML) on behalf of the GIMEMA working party on chronic myeloid leukemia (GIMEMA-CML).
Lacobucci, I
Testoni, N
Rosti, G
Amabile, M
Poerio, A
Soverini, S
Colarossi, S
Gnani, A
Ottaviani, E
Castagnetti, F
Terragna, C
Renzulli, M
Grafone, T
Cilloni, D
Pane, F
Saglio, G
Baccarani, M
BLOOD, 2005, 106 (11) : 320A - 320A
[23] INCIDENCE OF ABL KINASE DOMAIN MUTATIONS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH FAILURE OR SUBOPTIMAL RESPONSE TO FRONTLINE IMATINIB TREATMENT - AN ANALYSIS BY THE GIMEMA WORKING PARTY ON CML
Soverini, S.
Colarossi, S.
Gnani, A.
Castagnetti, F.
Abruzzese, E.
Orlandi, E.
Tiribelli, M.
Breccia, M.
Specchia, G.
Palandri, F.
Poerio, A.
Amabile, M.
Iacobucci, I.
Ciccarese, F.
Rosti, G.
Baccarani, M.
Martinelli, G.
HAEMATOLOGICA, 2008, 93 : S71 - S71
[24] Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia
StCharles, Meaghan
Bollu, Vamsi K.
Hornyak, Elizabeth
Coombs, John
Blanchette, Christopher M.
DeAngelo, Daniel J.
BLOOD, 2009, 114 (22) : 870 - 870
[25] CARDIOVASCULAR EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FIRST-LINE: AN ANALISYS OF THE GIMEMA CML WP
Gugliotta, G.
Castagnetti, F.
Breccia, M.
Stagno, F.
Martino, B.
Fava, C.
Luciano, L.
Gozzini, A.
Carella, A. M.
Abruzzese, E.
Levato, L.
Usala, E.
Rossi, G.
Bocchia, M.
Tiribelli, M.
Cavazzini, F.
Salvucci, M.
Cedrone, M.
Trabacchi, E.
Binotto, G.
Venturi, C.
Soverini, S.
Cavo, M.
Specchia, G.
Alimena, G.
Pane, F.
Martinelli, G.
Saglio, G.
Baccarani, M.
Rosti, G.
HAEMATOLOGICA, 2015, 100 : 56 - 56
[26] DECLINING ROLE OF DISEASE TRANSORMATION AS A CAUSE OF DEATH IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB IN EARLY CHRONIC PHASE: A LONG-TERM ANALYSIS BY THE GIMEMA CML WP
Castagnetti, F.
Gugliotta, G.
Breccia, M.
Specchia, G.
Intermesoli, T.
Iurlo, A.
Martino, B.
Binotto, G.
Cavazzini, F.
Abruzzese, E.
Stagno, F.
Leoni, P.
Ferrero, D.
Rege-Cambrin, G.
Bocchia, M.
Gherlinzoni, F.
Palandri, F.
Soverini, S.
Alimena, G.
Pane, F.
Martinelli, G.
Cavo, M.
Saglio, G.
Baccarani, M.
Rosti, G.
HAEMATOLOGICA, 2014, 99 : 73 - 73
[27] HYPOPHOSPHATEMIA AS A PREDICTOR OF RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML) TREATED WITH IMATINIB
Garrido, T.
Amorim, M.
Gomes, P.
Trigo, F.
Guimaraes, J.
HAEMATOLOGICA, 2014, 99 : 339 - 339
[28] Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Hughes, Timothy P.
Saglio, Giuseppe
Kantarjian, Hagop M.
Guilhot, Francois
Niederwieser, Dietger
Rosti, Gianantonio
Nakaseko, Chiaki
De Souza, Carmino Antonio
Kalaycio, Matt E.
Meier, Stephan
Fan, Xiaolin
Menssen, Hans D.
Larson, Richard A.
Hochhaus, Andreas
BLOOD, 2014, 123 (09) : 1353 - 1360
[29] Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia
Nekoohesh, Ladan
Rostami, Shahrbano
Nikbakht, Mohsen
Mohammadi, Saeed
Babakhani, Davood
Alimoghaddam, Kamran
Ghahremani, Mohammad H.
Chahardouli, Bahram
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01): : E1 - E10
[30] Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
Arora, B
Kumar, L
Sharma, A
Wadhwa, J
Kochupillai, V
ANNALS OF ONCOLOGY, 2004, 15 (02) : 358 - 359

← 1 2 3 4 5 →